Study of Messenger RNA in Human Breast Cancer
Author Information
Author(s): R.A. Skilton, Y.A. Luqmani, R.A. McClelland, R.C. Coombes
Primary Institution: Ludwig Institute for Cancer Research
Hypothesis
The expression of the Md2 mRNA can serve as a predictor of response to endocrine therapy in breast cancer.
Conclusion
The presence of Md2 mRNA in breast cancer tissues correlates with a better response to endocrine therapy.
Supporting Evidence
- Md2 mRNA was found in 43% of breast carcinomas studied.
- Expression of Md2 correlated with treatment response in patients who had undergone endocrine therapy.
- Both Md2 and estrogen receptor status predicted treatment outcomes in about 76% of cases.
Takeaway
Researchers found a special type of RNA in breast cancer that can help doctors predict how well a treatment will work.
Methodology
The study involved screening a cDNA library from breast cancer cells and analyzing the expression of Md2 mRNA in various breast cancer samples.
Limitations
The study had a limited sample size and may not represent all breast cancer types.
Participant Demographics
Patients aged 29 to 85, with a mix of premenopausal (40%) and postmenopausal (60%) women.
Statistical Information
P-Value
0.041
Statistical Significance
p=0.041
Want to read the original?
Access the complete publication on the publisher's website